Browse by Medical Category
Division of Surgical Oncology
Accepting New Patients
Go To Programs
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Lubitz received her undergraduate and medical degrees at the University of Michigan. Following her internship at the University of Michigan, she completed general surgery training at New York Presbyterian Hospital/Weill-Cornell Medical College. During residency, she studied the genetic basis of thyroid cancer as a part of the NCI-Surgical Oncology Research Training Program. She then completed her clinical endocrine surgery fellowship in 2010 at the Massachusetts General Hospital and is now an Assistant Professor of Surgery at the Harvard Medical School in the Division of Surgical Oncology, and a member of the MGH Endocrine Surgery Unit.
Dr. Lubitz was also recognized as a one hundred honoree in 2017. Read more about how she is influencing thyroid cancer care across the world.
In addition to her clinical practice which focuses on both benign and malignant thyroid, parathyroid, and adrenal disease, Dr. Lubitz has clinical and translational research interests including prediction and decision-analytic modeling to assess the comparative effectiveness and improve the quality of care of patients with endocrine-related disorders. Her current projects involve identifying appropriate and effective diagnostic, surgical, and surveillance strategies for patients with primary hyperaldosteronism and thyroid cancer. She obtained a Master of Public Health through the Harvard School of Public Health and completed her fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training in 2013. She continues as a senior scientist at the MGH Institute for Technology Assessment.
View my most recent publications at PubMed
Research presented by Carrie C. Lubitz, MD, MPH, surgeon at Massachusetts General Hospital, suggests that a new blood-based, non-surgical test for patients with papillary thyroid cancer (PTC) has proven effective in detecting the presence of a genetic mutation known as BRAFV600E.
Back to Top